|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/9/2012 9:34:17 AM
BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals today announced that Walter Ogier, President and CEO, will participate on the panel “The New Kids on the Biotech Block: Trends in Early Stage Financing” this morning, October 9, 2012, at 9 am PT at the BIO Investor Forum in San Francisco, CA. In addition, Mr. Ogier will give a corporate presentation at 3 pm PT, including an update of its oral histone deacetylase 6 (HDAC6) inhibitor, rocilinostat (ACY-1215), which is currently in two Phase 1b combination clinical trials with Revlimid® (lenalidomide, Celgene) and Velcade® (bortezomib, Takeda Millennium) for the treatment of relapsed and relapsed/refractory multiple myeloma.
|
|
|
|
|
|
|
|
|
|
|